The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related Myocarditis

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT06393972
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Glucocorticoid Resistant ICIs-related Myocarditis

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The efficacy and safety of Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a single-arm, prospective, phase 2 trial

Key Dates

Start date
Jul 1, 2024
Status verified
Apr 2024
Primary completion
Nov 30, 2025
Completion
Nov 30, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacitinib
    Tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis

Primary Outcome Measure

All-cause mortality within three months [ Time Frame: The first three months after tofacitinib administration ]

Central Contacts